Table 6.
Distribution and comparison of diabetic patients with insomnia according to Insomnia Severity Index (ISI) categories within treatment groups (at baseline).
| ISI categories | Treatment groups | Total | p-value | |||
|---|---|---|---|---|---|---|
| T1 | T2 | T3 | T4 | |||
| No clinically significant insomnia | 0 (0.0%) | 1 (1.3%) | 1 (1.4%) | 4 (5.5%) | 6 (2.1%) | 0.0001 |
| Sub-threshold insomnia | 3 (4.4%) | 17 (22.7%) | 20 (27.0%) | 4 (5.5%) | 44 (15.2%) | |
| Clinical insomnia (moderate severity) | 42 (61.8%) | 42 (56.0%) | 45 (60.8%) | 45 (61.6%) | 174 (60.0%) | |
| Clinical insomnia (severe) | 23 (33.8%) | 15 (20.0%) | 8 (10.8%) | 20 (27.4%) | 66 (22.8%) | |
| Total | 68 (100.0%) | 75 (100.0%) | 74 (100.0%) | 73 (100.0%) | 290 (100.0%) | |
T1: Placebo (starch tablets 250 mg × 2).
T2: Magnesium (250 mg × 2).
T3: Potassium (250 mg × 2).
T4: Magnesium + potassium (250 mg × 2).